Treatment of blue phlebitis by in situ thrombolysis with a plasminogen activator
Marcon, J.L.; Favre, E.; Bonijoly, S.
Presse Medicale 18(24): 1209-1210
1989
ISSN/ISBN: 0755-4982 PMID: 2525767 Document Number: 346479
Document emailed within 1 workday
Related Documents
Schermer, E.; Streif, W.; Genser, N.; Frühwirth, M.; Trawöger, R.; Simma, B. 2000: Thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in 13 children: a case series Wiener Klinische Wochenschrift 112(21): 927-933Rinaldi, J.P.; Yassine, M.; Aboujaoudé, F.; Belhakem, H.; Alsagheer, S.; Ben Ahmed, F.; Lemarié, P.; Boursier, M.; Khalifé, K. 1999: Successful thrombolysis on an aortic valve prosthesis by plasminogen tissue activator during pregnancy Archives des Maladies du Coeur et des Vaisseaux 92(4): 427-430
Inoue, C.; Yano, T.; Tashiro, H.; Terasaki, H. 2002: A case of successful thrombolysis by recombinant tissue plasminogen activator for postoperative pulmonary thromboembolism Masui. Japanese Journal of Anesthesiology 51(2): 199-202
Chen, L.; Nichols, W.W.; Mattsson, C.; Teger-Nilsson, A.C.; Saldeen, T.G.; Mehta, J.L. 1996: Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis Journal of Pharmacology and Experimental Therapeutics 277(3): 1276-1283
Habib, S.S.; Abdel Gader, A.G.M.; Kurdi, M.I.; Suriya, M.O.; Al Aseri, Z. 2012: Tissue plasminogen activator and plasminogen activator inhibitor-1 levels in patients with acute myocardial infarction and unstable angina JPMA. Journal of the Pakistan Medical Association 62(7): 681-685
Han, X.M.; Chen, Z.Q.; Mao, H.M. 1990: Determination of plasma tissue type plasminogen activator and plasminogen activator inhibitor activity in patients with ischemic stroke Zhonghua Nei Ke Za Zhi 29(9): 544-546; 575-576
Yamada, R.; Yamada, S.; Ishii, A.; Tane, S. 1993: Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-1 in blood obtained from patients of idiopathic central serous chorioretinopathy Nippon Ganka Gakkai Zasshi 97(8): 955-960
De Moerloose, P.; Mermillod, N.; Amiral, J.; Reber, G. 1998: Thrombomodulin levels during normal pregnancy, at delivery and in the postpartum: comparison with tissue-type plasminogen activator and plasminogen activator inhibitor-1 Thrombosis and Haemostasis 79(3): 554-556
Glas-Greenwalt, P.; Hall, J.M.; Panke, T.W.; Kant, K.S.; Allen, C.M.; Pollak, V.E. 1986: Fibrinolysis in health and disease: abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura Journal of Laboratory and Clinical Medicine 108(5): 415-422
Fukao, H.; Yamamoto, K.; Matsuo, O. 1991: Levels of tissue-type plasminogen activator and plasminogen activator inhibitor 1 in disseminated intravascular coagulation syndrome Rinsho Byori. Japanese Journal of Clinical Pathology 39(7): 720-726
Shiba, E.; Kobayashi, T.; Yayoi, E.; Takatsuka, Y.; Koyama, H.; Takai, S.; Mori, T. 1992: Measurement of plasminogen activator and plasminogen activator inhibitor in breast cancer tissue: preliminary report Nihon Geka Gakkai Zasshi 93(1): 109
Wallnöfer, A.E.; van Griensven, J.M.; Schoemaker, H.C.; Cohen, A.F.; Lambert, W.; Kluft, C.; Meijer, P.; Kooistra, T. 1993: Effect of isotretinoin on endogenous tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in humans Thrombosis and Haemostasis 70(6): 1005-1008
Jia, X.F.; Hong, Z.; Fan, J.H.; Zhang, Y.M. 2016: Clinical effect of mechanical fragmentation combined with recombinant tissue plasminogen activator artery thrombolysis on acute cerebral infarction Journal of Biological Regulators and Homeostatic Agents 30(3): 821-826
Virji, M.A.; Aggarwal, S.; Kang, Y. 1989: Alterations in plasminogen activator and plasminogen activator inhibitor levels during liver transplantation Transplantation Proceedings 21(3): 3540-3541
Kobayashi, Y.; Fukuo, Y.; Shibuya, T.; Terashi, A. 1990: The correlation between the activity of tissue plasminogen activator (TPA), levels of tissue plasminogen activator inhibitor (PAI-1) antigen and serum lipids in healthy subjects Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 27(5): 578-583
Nelles, L.; Lijnen, H.R.; Van Nuffelen, A.; Demarsin, E.; Collen, D. 1990: Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA) Thrombosis and Haemostasis 64(1): 53-60
Harbeck, N.; Kates, R.E.; Look, M.P.; Meijer-Van Gelder, M.E.; Klijn, J.G.M.; Krüger, A.; Kiechle, M.; Jänicke, F.; Schmitt, M.; Foekens, J.A. 2002: Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424) Cancer Research 62(16): 4617-4622
Fujii, S.; Lucore, C.L.; Hopkins, W.E.; Billadello, J.J.; Sobel, B.E. 1990: Induction of synthesis of plasminogen activator inhibitor type-1 by tissue-type plasminogen activator in human hepatic and endothelial cells Thrombosis and Haemostasis 64(3): 412-419
Agresta, F.; Michelet, I.; Boni, V.; Tonietto, G. 1998: Thrombolysis with i.v. recombinant human tissue-type plasminogen activator in patients with bypass graft occlusion: a good adjunctive therapeutic mode (preliminary and case reports) Journal of Cardiovascular Surgery 39(5): 551-555
Higo, K.; Karasawa, A.; Kubo, K. 1991: Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)- ethylidene]-6,11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate in a canine model of femoral thrombosis Arzneimittel-Forschung 41(12): 1251-1255